Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
AMES, Iowa, April 30, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference on May 9 at 11:20 AM ET in Boston
- Bank of America Merrill Lynch Global Healthcare Conference 2018 on May 16 at 5:15 PM PT (8:15PM ET) in Las Vegas
A live webcast of both conference presentations will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events and Presentations.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
